Other
RCC
0
Pipeline Programs↗
2
Active Trials↗
2
Companies Involved↗
RCC is an early-stage landscape with 0 programs across 2 companies. The most active players are AstraZeneca, AnewPharma.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
7
clinical trials
Active, not recruiting2 · 29%
Unknown status2 · 29%
Terminated2 · 29%
Completed1 · 14%
Clinical Trials
Trial Activity
7 trials
High Dose IL 2 and Entinostat in RCC
Active, not recruiting·—·Phase 2·NCT03501381·46 enrolled
Exploratory Study Of The ERCC-1 Gene
Completed·—·N/A·NCT00846482·64 enrolled
Optimizing Pazopanib Exposure in RCC Patients
Terminated·IInteressenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.·Phase 2·NCT02089802·6 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)